Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Beactica, a Sweden-based fragment-based drug discovery company, has entered into an agreement with Janssen Research & Development, a division of Janssen Pharmaceutica.
Subscribe to our email newsletter
Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint, to generate small-molecule lead compounds against undisclosed targets of therapeutic interest to Janssen.
Reportedly, Janssen is the fourth global pharmaceutical company to enter into an agreement with Beactica over the past one and half years.
Beactica CEO Per Kallblad said fragment-based approaches to drug discovery are creating new pathways towards small-molecule leads of high-quality.